Detalhe da pesquisa
1.
Efficacy and safety of tixagevimab-cilgavimab versus SARS-CoV-2 breakthrough infection in the hematological conditions.
Cancer
; 130(1): 41-50, 2024 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37658645
2.
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy.
Cancer
; 130(8): 1270-1280, 2024 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38153814
3.
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome.
Cancer
; 129(11): 1704-1713, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36932983
4.
Multicentric Castleman Disease and Concurrent Hematological Disorders: The Occurrence of Plasmacytoma and the Hypotheses Arising from Literature Review.
Acta Haematol
; 146(4): 331-337, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37068478
5.
Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis.
Cancer
; 128(13): 2449-2454, 2022 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35363892
6.
Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome.
Cancer
; 127(15): 2657-2665, 2021 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33794557
7.
Second primary malignancy in myelofibrosis patients treated with ruxolitinib.
Br J Haematol
; 193(2): 356-368, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33222197
8.
Impact of comorbidities and body mass index on the outcome of polycythemia vera patients.
Hematol Oncol
; 39(3): 409-418, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-33590502
9.
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis.
Cancer
; 126(6): 1243-1252, 2020 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31860137
10.
Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts.
Br J Haematol
; 189(5): 888-903, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32017044
11.
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data.
Hematol Oncol
; 38(3): 372-380, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-32271957
12.
Immunoproteasome Genes Are Modulated in CD34+ JAK2V617F Mutated Cells from Primary Myelofibrosis Patients.
Int J Mol Sci
; 21(8)2020 Apr 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-32331228
13.
Immune off-target effects of Brentuximab Vedotin in relapsed/refractory Hodgkin Lymphoma.
Br J Haematol
; 185(3): 468-479, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30768678
14.
Occurrence of lymphoproliferative disorders during ruxolitinib treatment: May fedratinib be the turning point?
Hematol Oncol
; 42(2): e3259, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38402568
15.
Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib.
Hematol Oncol
; 37(4): 418-423, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-30985017
16.
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib.
Ann Hematol
; 98(4): 889-896, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-30515542
17.
α-Lipoic Acid Reduces Iron-induced Toxicity and Oxidative Stress in a Model of Iron Overload.
Int J Mol Sci
; 20(3)2019 Jan 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-30708965
18.
Monocytic myeloid-derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib.
J Cell Mol Med
; 22(2): 1070-1080, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29218828
19.
Patient-reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromes.
Cancer
; 124(6): 1251-1259, 2018 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29231969
20.
The use of erythropoiesis-stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinib.
Br J Haematol
; 182(5): 701-704, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29984826